ADC Therapeutics Past Earnings Performance
Past criteria checks 0/6
ADC Therapeutics's earnings have been declining at an average annual rate of -8.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 67.4% per year.
Key information
-8.4%
Earnings growth rate
14.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 67.4% |
Return on equity | n/a |
Net Margin | -345.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Mar 19ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
Mar 17ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Jan 18ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Dec 29An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Dec 14ADC Therapeutics: Navigating A Swirling Drain
Dec 01ADC Therapeutics: Slowly Moving Toward Solvency
Aug 29Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?
Jul 11ADC Therapeutics: Maybe A 2024 Story
May 29Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%
May 11ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business
Apr 18ADC Therapeutics stock slips after pricing stock offering by seller
Feb 02Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?
Jan 16Jose Carmona joins ADC Therapeutics as CFO
Dec 19ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M
Nov 08ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval
Sep 16ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11
Sep 09ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M
Aug 09Analysts Just Made A Meaningful Upgrade To Their ADC Therapeutics SA (NYSE:ADCT) Forecasts
Jul 21Sobi to pay ADC Therapeutics $55M upfront to license Zynlonta in Europe, other regions
Jul 08ADC Therapeutics begins dosing in study of Zynlonta combo for blood cancer subtype
Jun 29Is ADC Therapeutics (NYSE:ADCT) A Risky Investment?
Jun 22ADC Therapeutics SA (NYSE:ADCT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 06Growth Investors: Industry Analysts Just Upgraded Their ADC Therapeutics SA (NYSE:ADCT) Revenue Forecasts By 21%
Mar 05Revenue & Expenses BreakdownBeta
How ADC Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 70 | -240 | 106 | 4 |
30 Sep 23 | 123 | -179 | 111 | 17 |
30 Jun 23 | 184 | -181 | 124 | 17 |
31 Mar 23 | 182 | -199 | 134 | 17 |
31 Dec 22 | 210 | -157 | 143 | 17 |
30 Sep 22 | 157 | -166 | 146 | 17 |
30 Jun 22 | 94 | -187 | 143 | 17 |
31 Mar 22 | 80 | -195 | 142 | 17 |
31 Dec 21 | 34 | -230 | 136 | 17 |
30 Sep 21 | 17 | -252 | 129 | 0 |
30 Jun 21 | 4 | -200 | 116 | 0 |
31 Mar 21 | 0 | -254 | 100 | 0 |
31 Dec 20 | 0 | -246 | 77 | 0 |
30 Sep 20 | 0 | -226 | 53 | 0 |
30 Jun 20 | 0 | -237 | 35 | 0 |
31 Mar 20 | 1 | -135 | 19 | 0 |
31 Dec 19 | 2 | -116 | 14 | 0 |
30 Sep 19 | 3 | -112 | 11 | 0 |
30 Jun 19 | 3 | -111 | 11 | 0 |
31 Mar 19 | 2 | -117 | 10 | 0 |
31 Dec 18 | 1 | -123 | 9 | 0 |
31 Dec 17 | 2 | -90 | 8 | 0 |
Quality Earnings: ADCT is currently unprofitable.
Growing Profit Margin: ADCT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ADCT is unprofitable, and losses have increased over the past 5 years at a rate of 8.4% per year.
Accelerating Growth: Unable to compare ADCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: ADCT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.